Access News 8, Focus on Access Three Years On, February 2003

HIV/AIDS RESEARCH AND DEVELOPMENT TROPICAL & NEGLECTED DISEASES VACCINES

The Access Campaign three years on is addressed in this issue of AccessNews, as well as the fear of another meningitis epidemic, Roche's failing of HIV patients, fighting against neglected diseases, no agreements at Doha and HIV positive children.

Read, watch, share

Maria Atonio, 43-years-old farmer from Macomia, returns home after visiting MSF’s Clinic in Nanga to receive ART treatment and to have a medical appointment with MSF’s clinical officer to monitor her health.

Photo credit: MSF/Martim Gray Pereira

Press release

Press release |

06 February 2024

HIV/AIDS

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

5 min

Technical brief |

24 November 2023

HIV/AIDS

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Different medications a person living with HIV may take every day. Upper-left picture shows a first line treatment. Upper-right is a second-line treatment for patients who do not respond to first-line treatment. Bottom-left is a third-line treatment for patients who do not respond to first- and second-line treatments. Bottom-right is a dolutegravir pill, a new molecule that suppresses viral load much faster than others.

Access News 8, Focus on Access Three Years On, February 2003

Read, watch, share

Colombia takes significant next step to expand people’s access to affordable HIV treatment, and moves forward with compulsory license for HIV medicine dolutegravir

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

Open letter to ViiV to improve access to HIV prevention drug CAB-LA

Testimonies for access to HIV prevention drug CAB-LA

MSF refuses to sign ViiV’s last-minute NDA for access to most-effective HIV prevention drug CAB-LA

Colombia to challenge AIDS drug patents

CSO letter supporting Resolution 881/23 by Colombia on issuing a compulsory license for HIV drug dolutegravir